Authors
Yaqi Pang, Xifeng Han, Yueyue Zhang, Ailan Yu, Zongwang Zhang, Xueying Zhang
Published in
Metabolic brain disease. Volume 41. Issue 1. Nov 20, 2026. Epub Nov 20, 2026.
Abstract
Sepsis-associated encephalopathy (SAE) stands as one of the most severe complications of sepsis. Currently, the clinical management of SAE follows a comprehensive management strategy centered on treatment of the underlying sepsis, supplemented by symptomatic management of neurological dysfunction. The cornerstone of SAE management is the prompt and effective treatment of the underlying sepsis, including early source control, appropriate antimicrobial therapy, and comprehensive organ support, thereby mitigating the systemic inflammatory response that contributes to brain injury. On this basis, symptomatic and supportive management of brain dysfunction is crucial. Although no targeted specific drugs are currently available, future research will focus on targeting pathological pathways such as neuroinflammation, preserving mitochondrial function, and stabilizing the blood-brain barrier (BBB), with particular attention to how impaired astrocytic glutamate clearance, metabolic coupling, and synaptic regulation may translate glial dysfunction into neuronal bioenergetic failure, synaptic instability, delirium, and long-term cognitive impairment, with the aim of achieving genuinely neuroprotective therapy. This review summarizes the current evidence on the molecular pathology of SAE, with a particular focus on astrocyte-related mechanisms, including recent advances in the classification of astrocyte states, mitochondrial dysfunction, autophagy, and astrocyte-neuron interactions. In terms of therapeutic strategies, activating antioxidant pathways and modulation of autophagy have both shown potential therapeutic value. Future research should focus on developing multi-target synergistic intervention strategies, promoting the translation of basic research findings into clinical practice, and providing new directions for the precision prevention and control of SAE.
PMID:
43062773
Bibliographic data and abstract were imported from PubMed on 21 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 5
- Comments 0